Exhibit
10.26


 








 


HEALTHTABTM
EXPANDS TO BRITISH COLUMBIA IN SELECT SHOPPERS DRUG MART® LOCATIONS


 


VANCOUVER,
BRITISH COLUMBIA – October 26, 2021 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”)
announces that it has expanded patient testing with the HealthTabTM platform in select Shoppers Drug Mart® pharmacies in British
Columbia, bringing its diabetes screening program to Western Canada for the first time.


 


“The
launch in Shoppers Drug Mart pharmacies in Ontario has been very successful and we are very happy to see the program lay the groundwork
for expansion,” said Hector Bremner, Avricore Health’s CEO. “Having a real-time patient observation program reporting
seamlessly across 3000kms is very unique and we are very proud to deliver this innovation.”


 


This
expansion builds off the Master Agreement signed with Shoppers Drug Mart Inc. to pilot the HealthTabTM platform in May of
this year which brings patients access to point-of-care blood screening and health-data management for potential risks for developing
diabetes and cardiovascular conditions through the HealthTabTM-integrated Afinion 2TM analyzers by Abbott Rapid Diagnostics.


 


“Patient
feedback, along with that of our pharmacists, has been very positive in Ontario with respect to HealthTabTM and we are evaluating
how more patients can benefit from this type of service,” said Frank Hack, Director of Complex Care at Shoppers Drug Mart. “In
coming to British Columbia, we are hoping to learn more about patient needs and serve them in the best way possible.”


 


Shoppers
Drug Mart® pharmacies in five cities have now received their HealthTabTM systems and will begin offering screening tests to
patients with known conditions associated with pre-diabetes, or already identified as diabetic, to provide diagnostic support and pharmacist-led
consultation services. They are located at:


 


	 	●	#5
    Road & Cambie: 11800 Cambie Rd, Richmond, BC
	 	●	Kensington
    Square: 6508 East Hastings St, Burnaby, BC
	 	●	Thurlow
    & Davie: 1125 Davie St, Vancouver, BC
	 	●	Cedar
    Hills: 12830 96th Avenue, Unit #6, Surrey, BC
	 	●	Hillside
    Shopping Centre: 1644 Hillside Ave, Victoria, BC


 


To
find a location near you, please visit: healthtab.com/locations


 


HealthTabTM
Market Fast Facts


 


	 	●	Point-of-Care
    Testing Market to reach $50.6 Billion USD in 2025 (Source)
	 	●	Glucose
    monitoring (diabetes related) to make up the largest growth with the sector. (Source)
	 	●	Nearly
    13.6 Million Canadians expected to diabetic or prediabetic by 2030, with many undiagnosed (Source)
	 	●	Over
    1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
	 	●	Close
    to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it’s only after a heart attack they
    are diagnosed. (Source)
	 	●	There
    are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.


 




    	 



    	 



    

 








 





About
HealthTabTM


 


HealthTabTM
is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform
for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results
on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases,
such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTabTM has also recently added capabilities for bacterial
and viral tests, such as strep and COVID-19.



The HealthTabTM network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role
in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and
provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention &
management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration
through API.





About
Avricore Health Inc.


 


Avricore
Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving
pharmacy forward. Through its flagship offering HealthTabTM (a wholly owned subsidiary), its mission is to make actionable health
information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.


 


Contact:


 


Avricore
Health Inc.


Hector
Bremner, CEO 604-773-8943 

info@avricorehealth.com 


www.avricorehealth.com



 


Cautionary
Note Regarding Forward-Looking Statements 


 


Information
in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking
statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,”
“will,” “could,” “would,” “might,” “remains,” “to be,” “plans,”
“believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,”
“future,” “positioned,” “potential,” “project,” “remain,” “scheduled,”
“set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements.
In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing
thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTabTM
platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions,
estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information
available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately
prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of
risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current
expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic
conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the
date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence
of future events or circumstances, unless otherwise required to do so by law.


 


Neither
the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy